Skip to main content Skip to section navigation Skip to footer
CohBar, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Programs & Pipelines
    • Overview
    • Our Approach
    • CB4211
    • CB5138 Analogs
    • Posters & White Papers
  • Patient Resources
    • Overview
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Partners
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Mar 12, 2020 4:02pm EDT

CohBar Reports Fourth Quarter 2019 Financial Results and Provides Business Update

Mar 12, 2020 8:30am EDT

CohBar to Hold Investor Meetings at the ROTH Virtual Conference

Mar 02, 2020 4:30pm EST

CohBar to Announce 2019 Fourth Quarter Financial Results and Provide Business Update on March 12, 2020

Jan 28, 2020 9:00am EST

CohBar to Present at the 2020 BIO CEO & Investor Conference

Jan 22, 2020 9:00am EST

CohBar Appoints Jordyn Tarazi as Director of Investor Relations

Jan 08, 2020 9:00am EST

CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis

Dec 16, 2019 9:00am EST

CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis

Nov 06, 2019 4:04pm EST

CohBar Reports Third Quarter 2019 Financial Results and Business Update

Nov 05, 2019 9:00am EST

CohBar Completes Phase 1a and Initiates Phase 1b Stage of Clinical Trial of CB4211 Under Development for NASH and Obesity

Oct 24, 2019 9:00am EDT

CohBar to Announce 2019 Third Quarter Financial Results and Provide Business Update on November 6, 2019

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • …
  • Page 18
  • Next Pagearrow_forward
  • Email Alerts
  • Tear Sheet
  • Contacts
©2023 CohBar, Inc. All Rights Reserved.
Privacy Policy Sitemap Terms of Use